DEALS: Ligand sells cancer drugs for $205M


Ligand sells cancer drugs for $205M


DEALS

WHO

WITH

WHAT

SCOOP

Ligand Pharmaceuticals

Eisai

$205M sale

Ligand Pharmaceuticals has sold a line of cancer drugs to Eisai.

Daiichi Sankyo

Kearney Venture Partners

$60M investment

The deal allows Daiichi to strike collaborations with the biotech companies who gain funds from the venture group.

Sankyo

Ajinomoto

Licensing deal

Sankyo has gained the exclusive global rights to develop, manufacture and market the new diabetes drug AJD101.

Omeros

Nura

Cash/stock buyout

Omeros' acquisition will add Nura's work in schizophrenia and Parkinson's disease. The three investors in Nura are making an unspecified but "large" investment in Omeros.

Genzyme

AnorMed

Hostile takeover

Genzyme says it will pursue a hostile takeover of AnorMed with a tender offer of $8.55 per share, a 70 percent premium on the Canadian biotech's trading price.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.